Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Abstract

BACKGROUND GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. We report the 4-year outcomes from this study. METHODS This randomised, double-blind, phase 3 trial was conducted across 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years; had treatment-naive, histologically or cytologically confirmed stage IV NSCLC, irrespective of PD-L1 expression levels; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomised (2:1) by investigators using an interactive web response or voice response system via permuted blocks (block sizes of three or six, randomised within each stratum). Patients received histology-specific platinum-based chemotherapy combined with either sugemalimab (1200 mg; sugemalimab group) or placebo (placebo group) for up to four cycles, followed by for up to 35 cycles of maintenance therapy with sugemalimab alone for patients with squamous NSCLC and sugemalimab plus pemetrexed for patients with non-squamous NSCLC in the sugemalimab group, or placebo for patients with squamous NSCLC and placebo plus pemetrexed for patients with non-squamous NSCLC in the placebo group, administered intravenously. Treatment beyond 35 cycles was permitt…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(25)00198-6

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 24 references

Cited by

See all 23

Metadata

Authors
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., Zhuang, W., Cui, J., Chen, X., Lu, Y., Shen, H., Hu, C., Liu, J., Liu, Y., Wang, M., Li, X., Sun, P., Shu, Y., Zhou, J., Li, J., Gu, K., Wang, C., Zhao, H., Zhang, Y., Liu, C., Yang, H., Zhang, X., Ma, R., Li, L., Liang, L., Li, M., Wang, J., Wang, Q., Wang, B., Dai, H., Shi, Q., & Yang, J.
Affiliations
  • Tongji University (CN)
  • Peking University Cancer Hospital (CN)
  • Jinan Central Hospital (CN)
  • University of Science and Technology of China (CN)
  • Zhengzhou University (CN)
  • China Medical University (CN)
  • Third Affiliated Hospital of Harbin Medical University (CN)
  • Sichuan Cancer Hospital (CN)
  • Fudan University (CN)
  • Hunan Cancer Hospital (CN)
  • Fujian Provincial Cancer Hospital (CN)
  • First Hospital of Jilin University (CN)
  • Westlake University (CN)
  • Sichuan University (CN)
  • Second Affiliated Hospital of Zhejiang University (CN)
  • Second Xiangya Hospital of Central South University (CN)
  • First Affiliated Hospital of Dalian Medical University (CN)
  • First Hospital of China Medical University (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Yuhuangding Hospital (CN)
  • Jiangsu Province Hospital (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Liuzhou General Hospital (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Second Affiliated Hospital of Anhui Medical University (CN)
  • Zhejiang Cancer Hospital (CN)
  • Xinjiang Medical University (CN)
  • Suzhou Municipal Hospital (CN)
  • Affiliated Hospital of Qingdao University (CN)
  • Liaoning Cancer Hospital & Institute (CN)
  • Beijing Hospital (CN)
  • Peking University Third Hospital (CN)
  • Second Affiliated Hospital of Dalian Medical University (CN)
  • CStone Pharmaceuticals (China) (CN)
Corresponding author
Zhou, Caicun
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2025-07
Volume
26
Issue
7
Pages
887-897
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4411265566
Cited by
23
References
24
Citations by year
2026: 17 · 2025: 6
FWCI
15.12
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
sugemalimab, PD-L1 inhibitors, metastatic non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, long-term outcomes, progression-free survival, overall survival, maintenance therapy, squamous NSCLC, non-squamous non-small cell lung cancer, immune checkpoint inhibitors, treatment safety, adverse events
MeSH terms
Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(25)00198-6
The paper
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., Zhuang, W., Cui, J., Chen, X., Lu, Y., Shen, H., Hu, C., Liu, J., Liu, Y., Wang, M., . . . Yang, J. (2025). Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(25)00198-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.